The role of hypomethylating agents in myelodysplastic syndrome: Changing the management paradigm

Drorit G. Merkel; Arnon Nagler

doi:10.1586/17474086.2013.854699

The role of hypomethylating agents in myelodysplastic syndrome: Changing the management paradigm

Drorit G. Merkel^*, Arnon Nagler

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Review article › peer-review

Abstract

Modern treatment of myelodysplastic syndromes (MDS) with hypomethylating agents (HMAs) such as azacitidine (Vidaza) and decitabine (Dacogen) has changed the clinical landscape of these disorders. Novel drug combinations of HMAs with histone deacetylase inhibitor therapy may synergistically target different dysregulated molecular mechanisms within MDS clones. This article reviews current trial data concerning the use of the main HMAs in MDS patients where intensive chemotherapy and allogeneic stem cell transplantation is generally not an option. Collated data are presented of the clinical response outcomes, toxicity profiles and prognostic response criteria. Vidaza use in low-risk MDS cases, the selected place of allogeneic stem cell transplantation in older patients with significant comorbidity and the novel drug combination strategies for the future are discussed.

Original language	English
Pages (from-to)	665-676
Number of pages	12
Journal	Expert Review of Hematology
Volume	6
Issue number	6
DOIs	https://doi.org/10.1586/17474086.2013.854699
State	Published - 2013

Keywords

Decitabine
High risk
Hypomethylating agents
Int2
Myelodysplastic syndrome
Vidaza

Access to Document

10.1586/17474086.2013.854699

Cite this

@article{9b0c39583cd3453da235f73fc29bedd4,

title = "The role of hypomethylating agents in myelodysplastic syndrome: Changing the management paradigm",

abstract = "Modern treatment of myelodysplastic syndromes (MDS) with hypomethylating agents (HMAs) such as azacitidine (Vidaza) and decitabine (Dacogen) has changed the clinical landscape of these disorders. Novel drug combinations of HMAs with histone deacetylase inhibitor therapy may synergistically target different dysregulated molecular mechanisms within MDS clones. This article reviews current trial data concerning the use of the main HMAs in MDS patients where intensive chemotherapy and allogeneic stem cell transplantation is generally not an option. Collated data are presented of the clinical response outcomes, toxicity profiles and prognostic response criteria. Vidaza use in low-risk MDS cases, the selected place of allogeneic stem cell transplantation in older patients with significant comorbidity and the novel drug combination strategies for the future are discussed.",

keywords = "Decitabine, High risk, Hypomethylating agents, Int2, Myelodysplastic syndrome, Vidaza",

author = "Merkel, {Drorit G.} and Arnon Nagler",

year = "2013",

doi = "10.1586/17474086.2013.854699",

language = "אנגלית",

volume = "6",

pages = "665--676",

journal = "Expert Review of Hematology",

issn = "1747-4086",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - The role of hypomethylating agents in myelodysplastic syndrome

T2 - Changing the management paradigm

AU - Merkel, Drorit G.

AU - Nagler, Arnon

PY - 2013

Y1 - 2013

N2 - Modern treatment of myelodysplastic syndromes (MDS) with hypomethylating agents (HMAs) such as azacitidine (Vidaza) and decitabine (Dacogen) has changed the clinical landscape of these disorders. Novel drug combinations of HMAs with histone deacetylase inhibitor therapy may synergistically target different dysregulated molecular mechanisms within MDS clones. This article reviews current trial data concerning the use of the main HMAs in MDS patients where intensive chemotherapy and allogeneic stem cell transplantation is generally not an option. Collated data are presented of the clinical response outcomes, toxicity profiles and prognostic response criteria. Vidaza use in low-risk MDS cases, the selected place of allogeneic stem cell transplantation in older patients with significant comorbidity and the novel drug combination strategies for the future are discussed.

AB - Modern treatment of myelodysplastic syndromes (MDS) with hypomethylating agents (HMAs) such as azacitidine (Vidaza) and decitabine (Dacogen) has changed the clinical landscape of these disorders. Novel drug combinations of HMAs with histone deacetylase inhibitor therapy may synergistically target different dysregulated molecular mechanisms within MDS clones. This article reviews current trial data concerning the use of the main HMAs in MDS patients where intensive chemotherapy and allogeneic stem cell transplantation is generally not an option. Collated data are presented of the clinical response outcomes, toxicity profiles and prognostic response criteria. Vidaza use in low-risk MDS cases, the selected place of allogeneic stem cell transplantation in older patients with significant comorbidity and the novel drug combination strategies for the future are discussed.

KW - Decitabine

KW - High risk

KW - Hypomethylating agents

KW - Int2

KW - Myelodysplastic syndrome

KW - Vidaza

UR - http://www.scopus.com/inward/record.url?scp=84887919993&partnerID=8YFLogxK

U2 - 10.1586/17474086.2013.854699

DO - 10.1586/17474086.2013.854699

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 24191866

AN - SCOPUS:84887919993

SN - 1747-4086

VL - 6

SP - 665

EP - 676

JO - Expert Review of Hematology

JF - Expert Review of Hematology

IS - 6

ER -

The role of hypomethylating agents in myelodysplastic syndrome: Changing the management paradigm

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this